Sagimet Biosciences Inc. Cash and Restricted Cash
Sagimet Biosciences Inc. (SGMT) had Cash and Restricted Cash of $165.90 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $165.90M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $36.63M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $35.02M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $32.50M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $165.90M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $36.63M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $35.02M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $32.50M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $42.33M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $64.72M 10-Q · filed 2026-05-12 | |
| 2024-12-31 | $75.84M 10-Q · filed 2026-08-11 | |
| 2024-09-30 | $77.01M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $95.96M 10-Q · filed 2025-08-13 | $75.14M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $176.78M 10-Q · filed 2025-05-08 | |
| 2023-12-31 | $75.14M 10-K · filed 2026-03-11 | |
| 2023-09-30 | $101.84M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $158.00K 10-Q · filed 2024-08-14 | $18.51M 10-Q · filed 2023-08-21 |
| 2023-03-31 | $12.34M 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $158.00K 10-K · filed 2025-03-12 | |
| 2022-09-30 | $2.23M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $4.46M 10-Q · filed 2023-08-21 | |
| 2021-12-31 | $56.73M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |